[HTML][HTML] RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
HM Dabbous, MH El-Sayed, G El Assal, H Elghazaly… - Scientific reports, 2021 - nature.com
Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different
viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of …
viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of …
[HTML][HTML] Current status of oral antiviral drug treatments for SARS-CoV-2 infection in non-hospitalized patients
DV Parums - … science monitor: international medical journal of …, 2022 - ncbi.nlm.nih.gov
On 4 th November 2021, the first oral antiviral drug for COVID-19, molnupiravir (Lagevrio®),
received full regulatory approval from the Medicines and Healthcare Products Regulatory …
received full regulatory approval from the Medicines and Healthcare Products Regulatory …
[HTML][HTML] Making statistical sense of the molnupiravir MOVe-OUT clinical trial
K Thorlund, K Sheldrick… - The American Journal …, 2022 - ncbi.nlm.nih.gov
Oral therapies for the early treatment of COVID-19 may prevent disease progression and
health system overcrowding. A new oral therapeutic named molnupiravir has been …
health system overcrowding. A new oral therapeutic named molnupiravir has been …
[HTML][HTML] First-generation oral antivirals against SARS-CoV-2
Background Oral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …
[HTML][HTML] Molnupiravir—a step toward orally bioavailable therapies for Covid-19
R Whitley - New England Journal of Medicine, 2022 - Mass Medical Soc
The Covid-19 pandemic has resulted in substantial global morbidity and mortality as well as
disruption of the economies of virtually every country. 1 Some of this tragedy could have …
disruption of the economies of virtually every country. 1 Some of this tragedy could have …
Molnupiravir use and 30-day hospitalizations or death in a previously uninfected nonhospitalized high-risk population with COVID-19
Background Clinical benefit of molnupiravir (MPV) in coronavirus disease 2019 (COVID-19)–
infected subpopulations is unclear. Methods We used a matched cohort study design to …
infected subpopulations is unclear. Methods We used a matched cohort study design to …
New perspectives on antimicrobial agents: molnupiravir and nirmatrelvir/ritonavir for treatment of COVID-19
RL Atmar, N Finch - Antimicrobial agents and chemotherapy, 2022 - Am Soc Microbiol
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has emerged to cause
pandemic respiratory disease in the past 2 years, leading to significant worldwide morbidity …
pandemic respiratory disease in the past 2 years, leading to significant worldwide morbidity …
[HTML][HTML] The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era
The quest for effective drugs to treat COVID-19 has been a priority since the outbreak of the
disease. The clinical application of remdesivir has been greatly restricted by the need for …
disease. The clinical application of remdesivir has been greatly restricted by the need for …
Covid-19: UK becomes first country to authorise antiviral molnupiravir
E Mahase - 2021 - bmj.com
Interim phase III trial results, released through a press release by the drug's manufacturer,
MSD, found that molnupiravir reduced the risk of admission to hospital or death by around …
MSD, found that molnupiravir reduced the risk of admission to hospital or death by around …
[HTML][HTML] Real-world experience of the comparative effectiveness and safety of molnupiravir and nirmatrelvir/ritonavir in high-risk patients with COVID-19 in a …
Y Mutoh, T Umemura, T Nishikawa, K Kondo, Y Nishina… - Viruses, 2023 - mdpi.com
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …
patients with the 2019 coronavirus (COVID-19). However, little is known about their …